ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1176

VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
Abstract Number: 1490

Vitamin D Deficiency and Its Relationship with Inflammatory Biomarkers in SLE: A Focus on Neutrophil-to-Lymphocyte Ratio
Abstract Number: 1544

Voclosporin in Lupus Nephritis: Meta-Analysis of 6-Month and 1-Year Efficacy with 1-Year Safety Outcomes
Abstract Number: 0314

What changes in quality of life can be observed in patients with knee or hip OA prior to total hip or total knee replacement surgery ? data from the KHOALA cohort
Abstract Number: 2619

What Works? A Consolidated Framework for Implementation Research-Guided Exploration of Patient Safety in Rheumatology Practices
Abstract Number: 0707

When Can Support Lead to Missed Clinic Appointments in Patients with Systemic Lupus Erythematosus?
Abstract Number: 1408

When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Abstract Number: 2298

When Imaging and Biopsy Disagree: Diagnostic Value of Doppler Ultrasound and Histologic Features beyond the Focus Score
Abstract Number: 0139

When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
Abstract Number: PP02

When The Body Speaks But No One Listens: A Dermatomyositis Story Through a Public Health Lens
Abstract Number: PP01

When You Become the Story: A Journalist’s Approach to Managing Complex Care
Abstract Number: 2112

Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
Abstract Number: 0539

Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort
Abstract Number: 0391

Which score fits best? Correlation of clinical indices of Disease Activity and Ultrasound findings in Juvenile Idiopathic Arthritis during Transitional Care
Abstract Number: 2273

Who Achieved and Maintained Clinical Remission in the 2-Year UPHOLD Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].